ES2175650T3 - Anticonceptivos orales de dosis ultra baja con menos hemorragia menstrual y eficacia mantenida. - Google Patents

Anticonceptivos orales de dosis ultra baja con menos hemorragia menstrual y eficacia mantenida.

Info

Publication number
ES2175650T3
ES2175650T3 ES98850109T ES98850109T ES2175650T3 ES 2175650 T3 ES2175650 T3 ES 2175650T3 ES 98850109 T ES98850109 T ES 98850109T ES 98850109 T ES98850109 T ES 98850109T ES 2175650 T3 ES2175650 T3 ES 2175650T3
Authority
ES
Spain
Prior art keywords
less
hemorragy
contraceptives
monthly
ultra low
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98850109T
Other languages
English (en)
Inventor
Gary D Hodgen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medical College of Hampton Roads
Original Assignee
Medical College of Hampton Roads
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32043766&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2175650(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medical College of Hampton Roads filed Critical Medical College of Hampton Roads
Application granted granted Critical
Publication of ES2175650T3 publication Critical patent/ES2175650T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
  • Confectionery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

UN PROCEDIMIENTO DE CONTRACEPCION FEMENINO IMPLICA LA ADMINISTRACION DE UNA COMBINACION DE ESTROGENO Y PROGESTINA DURANTE 60-110 DIAS CONSECUTIVOS EN LOS QUE LAS CANTIDADES DIARIAS DE ESTROGENO Y PROGESTINA EQUIVALEN A APROXIMADAMENTE A ENTRE 5 Y 35 MCG DE ETINILESTRADIOL DE Y APROXIMADAMENTE ENTRE 0.025 Y 10 MG DE ACETATO DE NORETINDRONA, RESPECTIVAMENTE. LAS VENTAJAS COMPRENDEN UN MENOR FLUJO MENSTRUAL, MENOR ANEMIA DE LA PACIENTE, MENOR EXPOSICION TOTAL A LA MEDICACION, MAYOR NIVELES DE ACEPTACION Y MAS COMODO PARA EL ESTILO DE VIDA DE LAS PACIENTES.
ES98850109T 1997-06-23 1998-06-15 Anticonceptivos orales de dosis ultra baja con menos hemorragia menstrual y eficacia mantenida. Expired - Lifetime ES2175650T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/880,419 US5898032A (en) 1997-06-23 1997-06-23 Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy
CA002256977A CA2256977C (en) 1997-06-23 1998-12-23 Methods of extended use oral contraception

Publications (1)

Publication Number Publication Date
ES2175650T3 true ES2175650T3 (es) 2002-11-16

Family

ID=32043766

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98850109T Expired - Lifetime ES2175650T3 (es) 1997-06-23 1998-06-15 Anticonceptivos orales de dosis ultra baja con menos hemorragia menstrual y eficacia mantenida.

Country Status (10)

Country Link
US (2) US5898032A (es)
EP (1) EP0911029B1 (es)
JP (1) JPH1129481A (es)
AT (1) ATE216241T1 (es)
CA (1) CA2256977C (es)
DE (1) DE69804918T2 (es)
DK (1) DK0911029T3 (es)
ES (1) ES2175650T3 (es)
NO (1) NO982815L (es)
PT (1) PT911029E (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19549264A1 (de) * 1995-12-23 1997-06-26 Schering Ag Verfahren und Kit zur Kontrazeption
WO2001030355A1 (fr) 1999-10-25 2001-05-03 Laboratoire Theramex Medicament contraceptif a base d'un progestatif et d'un estrogene et son mode de preparation
FR2754179B1 (fr) 1996-10-08 1998-12-24 Theramex Nouvelle composition hormononale et son utilisation
US5898032A (en) 1997-06-23 1999-04-27 Medical College Of Hampton Roads Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy
US6251956B1 (en) 1998-08-20 2001-06-26 Ortho Pharmaceutical Corporation Combination progestin oral contraceptive regimen
DE19739916C2 (de) 1997-09-11 2001-09-13 Hesch Rolf Dieter Verwendung einer Kombination aus einem Gestagen und einem Estrogen zur kontinuierlichen Ovulationshemmung und ggf. gleichzeitigen Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen
EP1148884A4 (en) * 1998-11-12 2003-06-11 Warner Chilcott Lab Ireland Lt Contraceptive with graded progestin
US7297688B2 (en) 2000-06-08 2007-11-20 Wyeth Starter kit for low dose oral contraceptives
DE10045380A1 (de) * 2000-09-14 2002-04-04 Schering Ag Verfahren zur Kontrazeption und dessen Darreichungsform
WO2002102390A1 (en) 2001-06-18 2002-12-27 Noven Pharmaceuticals, Inc. Enhanced drug delivery in transdermal systems
US20030018018A1 (en) * 2001-07-10 2003-01-23 Medical College Of Hampton Roads Ultra low dose oral contraceptives with sustained efficacy and induced amenorrhea
WO2003049744A1 (en) * 2001-12-05 2003-06-19 Barr Laboratories, Inc. Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
US7772219B2 (en) * 2003-05-02 2010-08-10 Teva Women's Health, Inc. Methods of hormonal treatment utilizing extended cycle contraceptive regimens
AU2004257772B2 (en) * 2003-07-16 2009-12-17 Teva Women's Health, Inc. Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration
AU2004270698B2 (en) * 2003-09-04 2009-06-18 Pharmadesign Inc. Case with pill receiving sleeves for storing and dispensing pills
NZ545969A (en) * 2003-10-01 2008-07-31 Janssen Pharmaceutica Nv Extended triphasic contraceptive regimens
EP1535618A1 (en) * 2003-11-26 2005-06-01 Schering Aktiengesellschaft Pharmaceutical preparation for continuous hormonal treatment over a period of longer than 21-28 days comprising two estrogen and/or progestin compositions
US7569560B2 (en) 2004-03-19 2009-08-04 Warner Chilcott Company Llc Extended cycle multiphasic oral contraceptive method
DE102004019743B4 (de) 2004-04-20 2008-11-27 Bayer Schering Pharma Aktiengesellschaft Mehrphasenpräparat zur Kontrazeption auf der Basis eines natürlichen Estrogens
MY151322A (en) 2004-04-30 2014-05-15 Bayer Ip Gmbh Management of breakthrough bleeding in extended hormonal contraceptive regimens
DE102004026679A1 (de) 2004-05-28 2005-12-15 Grünenthal GmbH Hormonales Kontrazeptivum enthaltend eine Kombination aus Ethinylestradiol und Chlormadinonacetat
DE102004026671A1 (de) * 2004-05-28 2005-12-15 Grünenthal GmbH Darreichungsform zur hormonalen Kontrazeption
DE102004026670A1 (de) 2004-05-28 2005-12-15 Grünenthal GmbH Hormonales Kontrazeptivum enthaltend eine Kombination aus Ethinylestradiol und Chlormadinonacetat
US8501720B2 (en) * 2004-07-30 2013-08-06 Bayer Pharma AG Method for treatment of dysmenorrhea
AU2005294269B2 (en) * 2004-10-07 2011-07-28 Teva Women's Health, Inc. Methods of hormonal treatment utilizing ascending-dose extended cycle regimens
US20070111975A1 (en) * 2004-10-07 2007-05-17 Duramed Pharmaceuticals, Inc. Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens
US20060079491A1 (en) * 2004-10-08 2006-04-13 Andreas Sachse Method of female hormonal contraception using a fixed extended cycle hormonal preparation containing dienogest and ethinyl estradiol
EP1655031A1 (de) 2004-10-08 2006-05-10 Schering AG Dienogest enthaltendes Langzeit-Verfahren zur Empfängnisverhütung
US7704984B2 (en) * 2005-04-22 2010-04-27 Warner Chilcott Company, Llc Extended estrogen dosing contraceptive regimen
US8153616B2 (en) 2005-10-17 2012-04-10 Bayer Pharma Aktiengesellschaft Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same
WO2007089733A2 (en) * 2006-01-27 2007-08-09 Duramed Pharmaceuticals, Inc. Regimens for treatment of conditions related to estrogen deficiency
CA2640520C (en) * 2006-03-02 2014-04-22 Warner Chilcott Company, Inc. Extended cycle multiphasic oral contraceptive method
EP1930010A1 (de) 2006-10-20 2008-06-11 Bayer Schering Pharma Aktiengesellschaft Verwendung von Estradiolvalerat oder 17ß-Estradiol in Kombination mit Dienogest zur oralen Therapie für den Erhalt und/oder die Steigerung der weiblichen Libido
DE202007019049U1 (de) * 2007-11-05 2010-05-12 Bayer Schering Pharma Aktiengesellschaft Verwendung eines Gestagens in Kombination mit einem Estrogen zur Prophylaxe der Laktoseintoleranz bei der oralen Kontrazeption
KR20110045065A (ko) * 2008-09-16 2011-05-03 플레이텍스 프로덕츠, 엘엘씨. 월경 억제, 피임 및 호르몬 대체 요법을 위한 약제 및 이를 투여하는 방법
EP2343964A4 (en) 2008-10-08 2012-11-07 Agile Therapeutics Inc TRANSDERMAL ADMINISTRATION
CA2740005C (en) 2008-10-08 2016-11-01 Agile Therapeutics, Inc. Transdermal delivery
WO2010042607A1 (en) 2008-10-08 2010-04-15 Agile Therapeutics, Inc Transdermal delivery
CA2756222A1 (en) 2009-03-27 2010-09-30 Agile Therapeutics, Inc. Transdermal delivery
MX2017014768A (es) * 2015-05-18 2018-03-23 Agile Therapeutics Inc Composiciones anticonceptivas y metodos para mejorar la eficacia y modulacion de los efectos secundarios.
CA3234836A1 (en) * 2021-09-07 2023-03-16 Millicent Pharma Limited Contraceptive regimen including reduced level of estrogen

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4145416A (en) 1976-06-23 1979-03-20 Schering, A.G. Novel agents and novel methods for treatment of climacteric disturbances
US4390531A (en) * 1981-08-10 1983-06-28 Syntex Pharmaceuticals International Ltd. Method of contraception using peak progestogen dosage
US4826831A (en) 1983-08-05 1989-05-02 Pre Jay Holdings Limited Method of hormonal treatment for menopausal or post-menopausal disorders involving continuous administration of progestogens and estrogens
US4962098A (en) 1987-06-15 1990-10-09 Warner-Lambert Company Graduated estrogen contraceptive
US5208225A (en) * 1986-02-27 1993-05-04 Warner-Lambert Company Compositions containing fixed combinations
IE61236B1 (en) * 1986-07-15 1994-10-19 American Home Prod Combination dosage form for pre-menopausal women
US5108995A (en) * 1987-09-24 1992-04-28 Jencap Research Ltd. Hormone preparation and method
US5098714A (en) * 1989-11-16 1992-03-24 Alza Corporation Osmotic, oral dosage form for fertility control
MX9301121A (es) 1992-03-02 1993-09-01 Schering Ag Metodo y equipo para la contracepcion oral y regulacion de la menstruacion con estrogeno/progestina/aniprogestina.
DE4344462C2 (de) 1993-12-22 1996-02-01 Schering Ag Zusammensetzung für die Empfängnisverhütung
DE4411585A1 (de) * 1994-03-30 1995-10-05 Schering Ag Pharmazeutisches Kombinationspräparat zur hormonalen Kontrazeption
US5552394A (en) * 1994-07-22 1996-09-03 The Medical College Of Hampton Roads Low dose oral contraceptives with less breakthrough bleeding and sustained efficacy
DE19525017A1 (de) * 1995-06-28 1997-01-02 Schering Ag Pharmazeutisches Kombinatonspräparat, Kit und Methode zur hormonalen Kontrazeption
DE19531936A1 (de) 1995-08-17 1997-02-20 Schering Ag Kombinationspräparat zur Kontrazeption, Kits diese enthaltend und eine Methode diese verwendend
AU3888597A (en) 1996-07-26 1998-02-20 American Home Products Corporation Oral contraceptive
US5898032A (en) 1997-06-23 1999-04-27 Medical College Of Hampton Roads Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy
DE19739916C2 (de) 1997-09-11 2001-09-13 Hesch Rolf Dieter Verwendung einer Kombination aus einem Gestagen und einem Estrogen zur kontinuierlichen Ovulationshemmung und ggf. gleichzeitigen Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen
US6214815B1 (en) 1998-12-23 2001-04-10 Ortho-Mcneil Pharmaceuticals, Inc. Triphasic oral contraceptive
US20030018018A1 (en) 2001-07-10 2003-01-23 Medical College Of Hampton Roads Ultra low dose oral contraceptives with sustained efficacy and induced amenorrhea
WO2003049744A1 (en) 2001-12-05 2003-06-19 Barr Laboratories, Inc. Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
US20030219471A1 (en) 2002-03-11 2003-11-27 Caubel Patrick Michel Extended cycle estrogen and sulfatase inhibiting progestogen contraceptive regimens
US7772219B2 (en) 2003-05-02 2010-08-10 Teva Women's Health, Inc. Methods of hormonal treatment utilizing extended cycle contraceptive regimens
US20040251301A1 (en) 2003-05-05 2004-12-16 Niemann Amy C. Device for calculating anticipated days for menstruation
US20040222123A1 (en) 2003-05-06 2004-11-11 Barr Laboratories, Inc. Kit for pharmaceuticals
AU2004257772B2 (en) 2003-07-16 2009-12-17 Teva Women's Health, Inc. Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration
AU2004270698B2 (en) 2003-09-04 2009-06-18 Pharmadesign Inc. Case with pill receiving sleeves for storing and dispensing pills
NZ545969A (en) 2003-10-01 2008-07-31 Janssen Pharmaceutica Nv Extended triphasic contraceptive regimens

Also Published As

Publication number Publication date
US5898032A (en) 1999-04-27
EP0911029A3 (en) 2000-03-29
DK0911029T3 (da) 2002-06-17
CA2256977A1 (en) 2000-06-23
DE69804918D1 (de) 2002-05-23
ATE216241T1 (de) 2002-05-15
EP0911029B1 (en) 2002-04-17
JPH1129481A (ja) 1999-02-02
USRE39861E1 (en) 2007-09-25
NO982815D0 (no) 1998-06-18
PT911029E (pt) 2002-09-30
EP0911029A2 (en) 1999-04-28
CA2256977C (en) 2008-11-25
NO982815L (no) 1998-12-28
DE69804918T2 (de) 2002-11-07

Similar Documents

Publication Publication Date Title
ES2175650T3 (es) Anticonceptivos orales de dosis ultra baja con menos hemorragia menstrual y eficacia mantenida.
ES2033850T3 (es) Forma farmaceutica consistente en una combinacion dosificada, destinada al tratamiento de las mujeres pre-menopausicas.
DE68928897T2 (de) Verfahren und system zur empfängnisverhütung
NO316257B1 (no) Anvendelse av en sammensetning av et östrogen og et gestagen, og et enfasetkombinasjonsprodukt for oral prevensjon
AR028809A1 (es) Un metodo anticonceptivo y una unidad anticonceptiva oral trifasica
JPH0395121A (ja) 前更年期のホルモン異常の治療用、更年期のホルモン補充療法用、アンドロゲン誘引性障害の治療用および避妊用医薬
NZ333750A (en) Monophasic contraceptive method and kit comprising a combination of a progestin and estrogen
GB1459675A (en) Method for the prevention of conception
HUP9900612A2 (hu) Új hormonális gyógyászati készítmények, valamint a készítmények alkalmazása ösztrogénpótlásra
ATE278406T1 (de) Orales contrazeptivum
ATE249222T1 (de) Biphasische orale verhuetungsmethode und kit die eine kombination von progestin und eines oestrogens enthalten
IT1243978B (it) Farmaco per uso umano, ad azione contraccettiva ed oncostatica preventiva, nei tumori del seno, dell'utero e nel melanoma.
HUP0300750A2 (hu) Gesztagéneken alapuló gyógyszerkészítmények dermális alkalmazáshoz

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 911029

Country of ref document: ES